Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans.
The Type 2 precursor plasmacytoid dendritic cells (pDC) represent the most important cell type in antiviral innate immunity. To understand the function of pDC during hepatitis B virus infection, the frequency and function of circulating pDC were analyzed by flow cytometric analysis, and IFN-alpha secretion of total PBMCs was determined by ELISA assay in 25 healthy subjects and 116 patients at various stages of chronic hepatitis B virus infection (CHB). The number of circulating pDC was found to be significantly lower in patients with CHB and associated liver cirrhosis (LC). The ability of PBMCs to secrete IFN-alpha also decreased significantly. There was a corresponding decrease of circulating NK cells and CD8+ T cells. We observed that lamuvidine antiviral therapy restored the number of circulating pDC and there was a reversal of pDC frequency with the control of HBV replication in chronic HBV patients, indicating these subjects are unlikely to be totally immunocompromised. The decrease of pDC was found to be related to nosocomial infections in LC patients. Our results suggest that CHB patients probably have a quantitative and qualitative impairment of circulating pDC or NK cells, which may be associated with HBV persistent infection as well as the nosocomial infections that arise in LC patients.
Duan
Xue-Zhang
XZ
Research Centre of Biological Therapy, Beijing Institute of Infectious Diseases, Beijing 302 Hospital, Beijing, People's Republic of China.
Wang
Min
M
Li
Han-Wei
HW
Zhuang
Hui
H
Xu
Dongping
D
Wang
Fu-Sheng
FS
D000328:Adult; D001772:Blood Cell Count; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D016022:Case-Control Studies; D003428:Cross Infection / Q000209:etiology; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000209:etiology / Q000276:immunology* / Q000821:virology; D006801:Humans; D007113:Immunity, Innate; D016867:Immunocompromised Host; D016898:Interferon-alpha / Q000378:metabolism; D007694:Killer Cells, Natural / Q000473:pathology; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008103:Liver Cirrhosis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014779:Virus Replication
D016898:Interferon-alpha; D019259:Lamivudine